GW Henssler & Associates Ltd. Cuts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GW Henssler & Associates Ltd. cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 199,765 shares of the medical equipment provider’s stock after selling 1,739 shares during the quarter. Zimmer Biomet accounts for approximately 1.3% of GW Henssler & Associates Ltd.’s holdings, making the stock its 29th biggest holding. GW Henssler & Associates Ltd. owned approximately 0.10% of Zimmer Biomet worth $21,565,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ZBH. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at about $28,000. Bangor Savings Bank bought a new position in shares of Zimmer Biomet during the third quarter valued at about $31,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the third quarter worth about $35,000. Finally, R Squared Ltd bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $63,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.1 %

NYSE:ZBH opened at $109.36 on Monday. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90. The company’s 50-day simple moving average is $107.94 and its 200 day simple moving average is $108.26. The firm has a market capitalization of $21.77 billion, a P/E ratio of 20.79, a PEG ratio of 1.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet’s payout ratio is currently 18.25%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, January 29th. Truist Financial raised their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Finally, Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.